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Both levetiracetam and phenytoin were effective in controlling seizure activity for established 
status epilepticus 
 
Levetiracetam was not significantly superior to phenytoin in seizure cessation. 
 










Objectives: To compare the efficacy and safety of levetiracetam and phenytoin for the 
treatment of established status epilepticus 
Methods In this systematic review, we searched Medline, Embase, and Cochrane databases 
from their inception with no language restrictions until May 8, 2019, for randomized controlled 
trials comparing the efficacy and safety of levetiracetam and phenytoin for the treatment of 
established status epilepticus. A meta-analysis was conducted to calculate the risk ratio (RR) 
using random-effects models.  
Results:  We identified six trials with a total of 765 participants. Levetiracetam was not 
associated with an increased rate of clinical seizure cessation within 15 min compared with 
phenytoin (RR, 1.03; 95%CI, 0.92-1.16; I2=23%; levetiracetam, 65.1 % [241/370] vs phenytoin, 
64.3 % [222/345];19 more events [95% CI, -51 to 103] per 1000 participants; moderate-quality 
evidence). The sample size met the optimum size in trial sequential analysis. There were also 
no statistically significant effects on all-cause mortality (RR, 0.88; 95% CI, 0.40-1.97; I2=0%), 
serious adverse events (RR, 0.51; 95% CI, 0.19-1.36; I2=0%), or any adverse events (RR, 0.95; 
95% CI, 0.67-1.34; I2=0%).  
Conclusions: Medium-quality evidence suggested that levetiracetam was not significantly 
superior to phenytoin in seizure cessation in patients with established status epilepticus.  
 





Convulsive status epilepticus is the second most common neurologic emergency, with an annual 
incidence of 10–40 cases per 100,000 people.[1, 2] Morbidity and mortality are considerable, 
and thus, timely termination of convulsive status epilepticus is the primary goal of 
management.[3-5]  Benzodiazepines, typically lorazepam or diazepam, are used as first-line 
therapy for status epilepticus.[6-8] However, benzodiazepines fail to terminate convulsive 
status epilepticus in about 40–60% of patients. The neurocritical care society guideline 
recommend phenytoin, levetiracetam, or valproate for the treatment of benzodiazepine-
refractory status epilepticus, also known as established status epilepticus. [Brophy et al 2012] 
Yet, only fosphenytoin (a precursor drug to phenytoin) is approved by the Food and Drug 
Administration (FDA) for this indication in adults, with no second-line treatments approved for 
children. [6-8] Further, evidence for this indication is sparse. Most evidence for phenytoin came 
from RCTs where phenytoin was administered as a second-line drug irrespective of whether 
status epilepticus was controlled by benzodiazepines; the studies did not demonstrate 
benzodiazepine-refractory status epilepticus.    
Levetiracetam, a newer anticonvulsant, has been viewed as a potential alternative to phenytoin 
for the treatment of established status epilepticus.[2] Levetiracetam can be given more rapidly 
by intravenous infusion (5 min) than phenytoin (20 min).[10] In observational studies, 
levetiracetam was superior to phenytoin in higher seizure cessation rates [11] and less serious 
adverse events[12] for the treatment of established status epilepticus. However, data from 
randomized controlled trials conducted so far does not support the use of one drug over 
another.[13, 32, 33] A systematic review and meta-analysis of two small trials did not find a 
statistically significant difference between levetiracetam and phenytoin, likely due to the 




Since the publication of that review, several trials[15-18] on this topic have become available, 
resulting in a combined sample size that is 5 times greater than the previous meta-analysis. 
Therefore, we performed a systematic review and meta-analysis to compare the efficacy and 
safety of levetiracetam versus phenytoin as the treatment of established status epilepticus. We 
also performed trial sequential analyses to identify if firm evidence is reached in cumulative 
studies.  
 
2 MATERIALS AND METHODS 
2.1	Protocol	and	guidance	
This study protocol and hypotheses is registered on the Open Science Framework 
(https://osf.io/b3zjn). The systematic review was conducted following the recommendations of 
The Cochrane Handbook for Systematic Reviews of Interventions[19] and the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[20] The 
PRISMA checklist is presented in Supplement eTable 1. Ethical approval was not obtained 
because this is a systematic review. 
 
2.2	Eligibility	criteria	 	
Inclusion criteria following PICOS (population, interventions, comparators, outcomes, and 
study design): 




(generalized or focal) despite first-line antiepileptic drugs (e.g., benzodiazepines) . Status 
epilepticus was defined as convulsive seizures lasting >5 minutes  
(2) Intervention: Intravenous levetiracetam.  
(3) Comparison: Intravenous phenytoin (fosphenytoin in the USA)  
(4) Outcome: The primary outcome was clinical seizure cessation within 15 min. Secondary 
outcomes were all-cause mortality, admission to critical care, and good functional outcome.  
(5) Study design: Randomized controlled trials 
Exclusion Criteria: Types of myoclonic, absence, or non-convulsive status epilepticus. 
2.3	Data	Sources	 	
We searched the databases Medline (from 1956 to May 8, 2019), Embase (from 1976 to May 
8, 2019), and Cochrane databases (from 1992 to May 8, 2019) . We also checked the reference 
lists of previous reviews for additional studies. We searched trial registries on ClinicalTrials.gov 
for ongoing studies or the availability of completed studies. We did not use any language 




After removal of duplicates, two authors (YZ and LJ) independently screened the title and 
abstracts of the search results. The full text of the remaining papers was assessed independently 







Two authors (YZ and YF) independently extracted data on study characteristics and event rates 
from the eligible trials into standardized collection forms. The following baseline 
characteristics were extracted from the included studies: key study characteristics (e.g., first 
author, year of publication, study design, country in which the study was performed and number 
of cite, study period, number of included patients, sex, age, initial dosages) and quantitative 
outcomes (clinical seizure cessation, all-cause mortality, admission to critical care). The data 
was collected on an intention-to-treat principle. Disagreements between the two authors were 
resolved by a third reviewer (FF).  
 
2.6	Risk	of	Bias,	Publication	Bias,	and	Quality	of	Evidence	
Two authors (FF and LL) independently assessed the risk of bias with the Cochrane 
Collaboration risk of bias tool across five domains (sequence generation, allocation 
concealment, blinding, detection bias, and attrition bias).[21] Each domain was assessed as 
either low, unclear, or high risk of bias. Disagreements between the two authors were resolved 
by a third reviewer (FF). Two authors (YZ and YF) independently rated the confidence in the 
estimates of effect for each outcome using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE).[22] We assessed the small-study effect using a visual 




trials were pooled.[23]   
 
2.7	Data	synthesis	 	
All statistical analyses were performed using RevMan (5.3.3; The Cochrane Collaboration). 
Pooled effect sizes were calculated using a random-effects model. For dichotomous outcomes, 
we calculated risk ratios (RR) and 95% CIs with the Mantel–Haenszel method. Statistical 
significance testing was 2-sided and P<.05 was considered statistically significant. 




We conducted trial sequential analysis[25] for the primary outcome to explore whether 
cumulative data were adequately powered to evaluate outcomes. Trial sequential analysis was 
used to maintain an overall 5% risk of type I error, an anticipated relative risk reduction of 
20.0%, and a control event rate of 67.0%. TSA viewer version 0.9.5.10 Beta (Copenhagen Trial 
Unit, Centre for Clinical Intervention Research, Copenhagen, DE. 2016) was used for analysis. 
 
2.9	Subgroup	analysis	




stratified trials by age into two categories: children (age<18 years old) vs adults (age>18 
years old).  
 
2.10	Sensitivity	analyses	
Sensitivity analyses were done to explore potential heterogeneity by (1) excluding trials at each 
time, (2) using fixed-effect models, (3) excluding trials with a high risk of bias, (4) excluding 




Details of the study selection process are presented in Figure 1. We identified 965 studies in the 
systematic electronic literature search, and we also identified two additional trials after 
checking previous reviews. After removal of records according to pre-specified criteria, 13 full-
text reports were reviewed for potential eligibility. After exclusion of incomplete reports[14, 
26-31], six trials[15-18, 32, 33] were deemed eligible and included in the meta-analysis. The 
reasons for excluding trials that underwent full-text review are presented in Supplemental 
eTable 3. 
The key characteristics of all included studies are summarized in Table 1 and eTable 4-5. Across 
the six trials, 765 participants were enrolled (390 randomized to levetiracetam, 375 randomized 








Risk-of-bias assessments are reported in Supplement eFigure 1 and 2. Three trials[15, 17, 18] 
were deemed at high risk of bias because of the unblinded design; one trial[32] was high risk 
for selection bias. Two trials[16, 33] were ranked as unclear risk. Key findings of GRADE 
assessment for main outcomes are shown in Supplement eTable 6.  
 
3.3	Primary	outcome	
Of the six trials included in the meta-analysis, five trials were included in primary outcome 
assessement as they provided information on clinical seizure cessation within 15 min. The rates 
of seizure cessation within 15 min were 65.1 % (241/370) in the levetiracetam group and 64.3 % 
(222/345) in the phenytoin group. Compared with phenytoin, levetiracetam was not associated 
with a high rate of clinical seizure cessation (RR, 1.03; 95%CI, 0.92-1.16; I2=23%; moderate-
quality evidence; Figure 2). We did not perform analysis to detect small-study effects due to the 
low number of trials. The planned subgroup analysis of adult and pediatric patients was not 
performed, because there were no trials that only included adults (age > 18 years). Sensitivity 
analyses showed similar results in clinical seizure cessation for all of the following: excluding 
trials one at a time, using fixed-effect models, excluding trials with a high risk of bias, excluding 




seizure cessation, the effect estimate lay outside the futility boundary for relative risks of 20%, 
meaning there is reliable evidence that overall, levetiracetam compared with phenytoin does 
not increase the rate of clinical seizure cessation by 20% (Supplement eFigure 3). However, in 
the pediatric subgroup, trial sequential analyses showed that the optimum size was not met 
(Supplement eFigure 4). 
 
3.4	Secondary	outcomes	
The forest plots of secondary outcomes are shown in Figure 3. Similar with primary outcome, 
levetiracetam was not superior to phenytoin in good functional outcome (RR, 1.05; 95% CI, 
0.90-1.23; I2=0%), admission to critical care (RR, 1.15; 95% CI, 0.97-1.36; I2=0%), or all-cause 
mortality (RR, 0.88; 95% CI, 0.40-1.97; I2=0%). 
	
4 Discussion 
In this meta-analysis of 6 trials with a total of 765 patients, we did not detect a significant 
difference between phenytoin and levetiracetam for the treatment of established status 
epilepticus with regards to any outcome, including clinical seizure cessation within 15 minutes 
and safety. Both drugs were effective in controlling seizure activity after the failure of first-line 







A previous review with a similar analysis approach showed the absence of a statistically 
significant difference because of the lack of statistical power to detect a difference.[14] The 
previous review only included two small trials with a total of 157 adults. Hence there was 
considerable uncertainty around the conclusions and children could not be examined. Our 
findings are consistent with the previous review. However, our study differed in the following 
four aspects. First, our comparative analysis was the largest to date, comprising data, five times 
larger than the previous study, which has made it possible to improve the precision of the 
outcomes. Second, trial sequential analysis showed that our data meet the minimum information 
size, which increased the reliability of the results. Third, we have also provided absolute as well 
as relative risks and a formal rating of the quality of the evidence and documented the credibility 
of the primary outcome. Fourth, we quantified several new findings, including no difference 
between both groups in all-cause mortality, serious adverse events, non-serious adverse events, 
and admission to critical care.  
After this study was submitted for initial review, an additional trial, the Established Status 
Epilepticus Treatment Trial (ESETT), was published.[13] The ESETT trial compared the 
efficacy and safety of levetiracetam, fosphenytoin, and valproate in children and adults with 
established status epilepticus, and found the three drugs were associated with similar incidences 
of seizure cessation. Though our results were similar to that of the ESETT trial, our study 
quality was inferior to the ESETT trial, which is a high-quality, double-blind, multi-site 
randomized trial that was well-powered to detect a difference between levitiracetam, 





We conducted this study based on an a priori protocol that defined a rigorous methodological 
approach based on the Cochrane Handbook. We also assessed the quality of evidence using 
GRADE (and found the quality for many critical outcomes moderate) and the minimum 
information size using in the trial sequential analysis in the overall analysis (and found our data 
meet the minimum information size).  
This study had limitations. First, the main limitation of this study was the overall moderate 
methodological quality of included trials. The two large trials were delivered without blinding.  
Second, the number of included trials was limited, and thus we were unable to evaluate the bias 
resulting from small-study effects (i.e. smaller studies show greater treatment effects than larger 
ones). However, the potential bias may be low because all included trials had negative results.  
Third, although there were no significant difference between rates of adverse events in 
levetiracetam and phenytoin, levetiracetam showed a trend in reduced risk of serious adverse 
events. Also, caution is required when interpreting adverse events due to the extremely wide 
confidence intervals. 
Fourth, trials included in this systematic review differed in their definition of convulsive status 
epilepticus, including the time of prolonged seizures and types of status epilepticus (generalized 
convulsive SE / focal motor SE). It may be a possible source of clinical heterogeneity. 
Fifth, we used trial sequential analyses to control the risks of type I and type II errors. However, 
the use of trial sequential analyses has been criticized, and it appears more controversial to 
ignore the risks of random errors.[34] Interpretation of trial sequential analyses is complex and 
should be considered with caution. 




demonstrated refractoriness to the first-line benzodiazepine treatment. Four of six trials 
described in their methods section how patients who failed the first-line benzodiazepine was 
enrolled and patients who responded to benzodiazepine was excluded. However, two trials 
allocated second-line treatments immediately after benzodiazepine administration.[15,33] The 
two trials did not provide time for observing the cessation of epileptic activity, and some of the 
patients may have seizure cessation not attributable to the second-line treatment, leading to 
clinical heterogeneity in our meta-analysis. 
 
4.3	Implications	 	
In the past decade, guidelines recommend phenytoin as the treatment of established status 
epilepticus after the failure of first-line treatment with benzodiazepines.[6-8] The use of 
alternative drugs had been limited by the lack of high-quality evidence for this indication. 
Results of our meta-analysis of randomized trials suggests that levetiracetam and phenytoin had 
similar efficacy and safety for the treatment of established status epilepticus. Another recently 
published head-to-head trial provided stronger evidence for the same conclusion. In light of the 
evidence, recommendations for second-line treatment could be expanded.  
Nonetheless, our findings should be interpreted with caution because a planned subgroup 
analysis stratified by age was not performed. The subgroup analysis was not conducted was due 
to a lack of trials that enrolled only adults, and the sample size of trials conducted in children 





This meta-analysis did not find evidence supporting that levetiracetam was superior to 
phenytoin in cessation rate of clinical seizure within 15 minutes. 
We confirm that we have read the Journal’s position on issues involved in ethical publication and 
affirm that this report is consistent with those guidelines 
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Figure descriptions:  
Figure 1 Search strategy and final included and excluded studies 
Figure 2 Association of levetiracetam versus phenytoin with clinical seizure cessation.  
Figure 3 ssociation of levetiracetam versus phenytoin with all-cause mortality, admission to 

























Table 1 Characteristics of trials included 
Trials Country Site Age 
range 
Patients, N Mean age Female, % Initial Dosages 
LEV PHT LEV PHT LEV PHT LEV PHT 
Mundlamuri 2015 India 1 > 15 50 50 34.78±13.64 33.24±13.39 36 44 25 mg/kg 20 mg/kg at 50 mg/min 
Chakravarthi 2015 India 1 > 14 22 22 39.00±18.40 31.82±12.68 45 32 20 mg/kg at 100 mg/min 20 mg/kg at 50 mg/min 
Gujjar 2017 Oman 1 > 15 22 30 38±19 37±19 41 30 30 mg/kg over 30 min 20 mg/kg over 30 min 
Senthilkumar 2018 India 1 0.25-12 25 25 2.28±2.19 3.34±3.36 28 36 30mg/kg over 7 min 20mg/kg 
Dalziel 2019 Australia, New Zealand 13 0.25-16 119 114 3.8±3.8 4.0±3.9 50 54 20mg/kg over 5 min 20 mg/kg over 20 min 
Lyttle 2019 UK 30 0.5-18 152 134 2.7 2.7 51 46 40 mg/kg over 5 min 20 mg/kg (max 2g) 
 
